期刊文献+

联合应用氯喹增加人胶质瘤细胞U343细胞对Bcl-2抑制剂ABT737的敏感性 被引量:1

Combination of chloroguine increased the sensitivy of human glioma cells(U343)to Bcl-2inhibitor ABT737
下载PDF
导出
摘要 目的探讨Bcl-2抑制剂ABT737联合氯喹的抗肿瘤作用。方法选用人胶质瘤细胞U343细胞系,应用MTT方法检测ABT737和(或)氯喹对U343细胞活性的影响,western blot检测ABT737和(或)氯喹对U343细胞凋亡通路相关蛋白的作用。结果 ABT737显著降低细胞生存率,增加U343细胞凋亡相关蛋白Cleaved PARP、Cleaved Caspase-3及细胞色素C(cytochrome c)表达。当氯喹与ABT737联用时,二者联用与单用ABT737组相比,细胞活性显著降低,显著下调凋亡通路相关蛋白Cleaved PARP、Cleaved Caspase-3、细胞色素C表达。结论联用氯喹可提高人胶质瘤细胞U343细胞对Bcl-2抑制剂ABT737的敏感性。 Objective The purpose of this study is to investigate the effect of combination Bcl-2 inhibitor ABT737 with chloroquine.Methods Human glioma cell line U343 cells were chosen.The activity of U343 cells were determined by MTT.Apoptosis pathway-related proteins were determined by western blot.Results After U343 cells were treated with ABT737 for 24h,cell viability was significantly decreased in a dose-dependent manner.ABT737 concentration-dependently upregulated apoptosis-related protein (Cleaved PARP,Cleaved Caspase-3 and cytochrome C).When combined with chloroquine,the cell viability of the combination group was significantly reduced,compared with that of ABT737 alone group.The apoptosis-related proteins of the combination group (Cleaved PARP,Cleaved Caspase-3 and cytochrome C)expression were also significantly reduced,compared with those of ABT737 alone group.Conclusion The combination of chloroquine can increase the sensitivity of human glioma cells U343 cells to Bcl-2 inhibitor ABT737.
出处 《中国实验诊断学》 2014年第9期1402-1405,共4页 Chinese Journal of Laboratory Diagnosis
关键词 BCL-2 抑制剂 ABT737 氯喹 人胶质瘤细胞 U343 细胞 Bcl-2 inhibitor ABT737 chloroquine human glioma cells U343 cells
  • 相关文献

参考文献16

  • 1张淑兰,姚鹏,宫平.Bcl-2蛋白小分子抑制剂的研究进展[J].沈阳药科大学学报,2008,25(11):919-923. 被引量:2
  • 2Tilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al. An Inhibitor of Bcl-2 Family Proteins Induces Regression of Solid TumoursFJ]. Nature, 2005,435 (7042) : 677.
  • 3RW Rooswinkel,B Van de kooij,M Verheij,et al. Bcl-2 Is a Beta ter Abt-737 Target Than Bcl-xl Or Bcl-w and Only Noxa Overcomes Resistance Mediated By Mcl-1, Bfl-1, Or Bcl-h[J]. Cell Death & Disease,2012,3(8) :0.
  • 4Marina Konopleva,Rooha Contractor, Twee Tsao, et al. Mechanisms of Apoptosis Sensitivity and Resistance to the Bh3 Mimetic Abt-737 in Acute Myeloid Leukemia[J]. Cancer Cell, 2006, 10 (5) : 375.
  • 5Derek Yecies,Nicole E Carlson,Jing Deng,et al. Acquired Re- sistance to Abt 737 in Lymphoma Cells That Up-regulate Mcl-1 and Bfl-1[J]. Blood,2010,115(16) :3304.
  • 6Mark S Cragg, Claire Harris, Andreas Strasser, et al. Unleashing the Power of Inhibitors of Oncogenic Kinases Through Bh3 Mitactics[J1. Nature Reviews Cancer, 2009,9 (5) : 321.
  • 7李晓升,宋关鸿.评述氯喹的作用机制假说[J].中国人兽共患病杂志,1999,15(4):101-103. 被引量:9
  • 8CA Homewood, DC Warhurst, W Peters, et al. Lysosomes, Ph and the Anti-malarial Action of Chloroquine[J]. Nature, 1972, 235(7) :50.
  • 9Andrew FG Slater. Chloroquine:Mechanism of Drug Action'and Resistance In< I> Plasmodium Falciparum [J]. Pharmacology Therapeutics, 1993,57 (2):203.
  • 10John FR Kerr,Clay M Winterford,Brian V Harmon. Apoptosis. Its Significance in Cancer and Cancer Therapy[J]. Cancer, 1994, 73(8) :2013.

二级参考文献24

  • 1ADAMS J M, CORY S. The Bcl-2 protein family: arbiters of cell survival[J]. Science, 1998, 281:1322- 1326.
  • 2[ ADAMS J M, CORY S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential [ J ]. Current Opinion in Immunology, 2007,19:488 - 496.
  • 3PULLEY H, MOHAMMAD R. SmaU-molecule inhibitors of Bcl-2 protein[J]. Drug of the Future, 2004, 29(4) :369 - 381.
  • 4MANION M K, FRY J, SCHWARTZ P M, et al. Small-molecule inhibitors of Bcl-2[J]. Current Opinion in Investigational Drugs, 2006, 7(12) : 1077 - 1084.
  • 5LIU Wen-jing, BULGARU A, HAIGENTZ M, et al. The Bcl-2 family of protein ligands as cancer drugs: the next generation of therapeutics [ J ]. Curt Med Chemanti-Cancer Agents, 2003, 3 : 217 - 223.
  • 6DOSHI J M, TIAN De-feng, XING Cheng-guo. Structure-activity relationship studies of ethyl 2-amino-6- bromo-4-( 1-cyano-2-ethoxy-2-oxoethyl )-4Hchromene-3-carboxylate (HA14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer [ J ]. Journal of Medicinal Chemistry, 2006, 49 (26) :7731 - 7739.
  • 7[ WANG Y, SENADELL N, BOLOS J, et al. Obatoclax mesilate[ J ]. Drugs of the Future, 2007, 32 (3) .. 228 - 233.
  • 8KITADA S, LEONE M, SARETH S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotie polyphenols targeting B - cell lyrnphocyte/leukemia-2 proteins[J ]. Journal of Medicinal Chemistry, 2003, 46(20) :4259 - 4264.
  • 9WANG Guo-ping, COLESKA Z N, YANG Chao-ye, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins [ J ]. Journal of Medicinal Chemistry, 2006, 49(21) :6139 - 6142.
  • 10MOHAMMAD R M, GOUSTIN A S, ABOUKAMEEL A, et al. Preclinical studies of TW- 37, a new nonpeptidic small - molecule inhibitor of Bcl- 2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-l[J]. Clin Cancer Res, 2007, 13 : 2226 - 2235.

共引文献9

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部